Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
Want to see NRSN full AI Analyst Report?
Top Page
Neurosense Therapeutics Ltd.
(NASDAQ:NRSN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.87
▲(22.54% Upside)
Action:Reiterated
Date:04/29/26
The score is primarily weighed down by weak financial performance (no revenue, significant ongoing losses, negative free cash flow, and negative equity/declining assets). Technicals are mixed with longer-term downtrend signals, and valuation is not supportive due to negative earnings and no dividend.
Positive Factors
Robust Phase 2b survival and efficacy data
Statistically significant survival and functional benefits from the randomized Phase 2b trial materially de-risk PrimeC’s clinical profile. Durable, published efficacy across survival and biomarkers strengthens regulatory dialogue, supports a credible pathway to a pivotal Phase 3 program, and underpins long-term commercial potential in ALS.
Negative Factors
Deteriorated balance sheet and negative equity
Negative shareholders’ equity and a sharply shrinking asset base reflect cumulative losses and eroded financial flexibility. Over the medium term this constrains strategic optionality, raises refinancing reliance, and leaves the company vulnerable to funding shocks absent successful capital raises or rapid improvement in cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust Phase 2b survival and efficacy data
Statistically significant survival and functional benefits from the randomized Phase 2b trial materially de-risk PrimeC’s clinical profile. Durable, published efficacy across survival and biomarkers strengthens regulatory dialogue, supports a credible pathway to a pivotal Phase 3 program, and underpins long-term commercial potential in ALS.
Read all positive factors
Neurosense Therapeutics Ltd. (NRSN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.99M
Dividend YieldN/A
Average Volume (3M)944.42K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding35,349,810
10 Day Avg. Volume256,142
30 Day Avg. Volume944,423
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-12.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.55
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$6.00Price Target Upside745.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$714.07K
Neurosense Therapeutics Ltd. Business Overview & Revenue Model
Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation ...
How the Company Makes Money
null...
Neurosense Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -89.00K | -3.00K |
| EBITDA | -8.55M | -11.07M | -9.88M | -9.64M | -12.23M | -2.88M |
| Net Income | -8.66M | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M |
Balance Sheet | ||||||
| Total Assets | 1.68M | 1.03M | 4.58M | 3.19M | 7.71M | 11.43M |
| Cash, Cash Equivalents and Short-Term Investments | 666.00K | 166.00K | 3.38M | 2.64M | 7.09M | 11.06M |
| Total Debt | 0.00 | 170.00K | 73.00K | 142.00K | 211.00K | 1.83M |
| Total Liabilities | 2.20M | 2.59M | 1.99M | 4.94M | 2.09M | 2.42M |
| Stockholders Equity | -519.00K | -1.56M | 2.58M | -1.76M | 5.62M | 9.01M |
Cash Flow | ||||||
| Free Cash Flow | -2.00K | -7.68M | -10.14M | -8.38M | -7.66M | -1.56M |
| Operating Cash Flow | -2.00K | -7.67M | -10.13M | -8.35M | -7.59M | -1.54M |
| Investing Cash Flow | -7.00 | -8.00K | 1.00K | 3.47M | -3.54M | -17.00K |
| Financing Cash Flow | 651.00 | 4.43M | 10.91M | 3.98M | 3.69M | 11.90M |
Neurosense Therapeutics Ltd. Technical Analysis
Positive
0.71
Price Trends
0.78
Positive
0.85
Negative
0.98
Negative
Market Momentum
<0.01
Positive
51.47
Neutral
40.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Positive. The current price of 0.71 is below the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.78, and below the 200-day MA of 0.98, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.47 is Neutral, neither overbought nor oversold. The STOCH value of 40.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRSN.
Neurosense Therapeutics Ltd. Risk Analysis
Neurosense Therapeutics Ltd. disclosed 69 risk factors in its most recent earnings report. Neurosense Therapeutics Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If we fail to maintain compliance with Nasdaq's continued listing requirements, our shares may be delisted from the Nasdaq Capital Market. Q4, 2023
2.
If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
3.
Environmental, social and corporate governance, or ESG, issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation. Q4, 2023
Neurosense Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $91.40M | -11.50 | -185.74% | ― | 45.88% | 34.17% | |
45 Neutral | $321.75M | -11.50 | -56.32% | ― | ― | 43.48% | |
44 Neutral | $28.99M | -1.76 | 9999.00% | ― | ― | ― | |
42 Neutral | $6.15M | -1.40 | -92.74% | ― | 360.39% | 35.61% | |
42 Neutral | $17.91M | -2.94 | -108.76% | ― | -100.00% | 70.40% |
* Healthcare Sector Average
NRSN
Neurosense Therapeutics Ltd.
0.82
-0.70
-46.05%
TENX
Tenax Therapeutics
12.13
6.08
100.50%
CLGN
Collplant Holdings
0.43
-1.50
-77.93%
XCUR
Exicure
2.81
-7.23
-72.01%
NRXS
NeurAxis, Inc.
7.38
4.42
149.32%
Neurosense Therapeutics Ltd. Corporate Events
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
Apr 28, 2026
On April 28, 2026, NeuroSense Therapeutics Ltd. announced it had entered into a definitive agreement for a $600,000 insider-led private investment in public equity financing, selling 750,000 ordinary shares at $0.80 per share, a 6.7% premium to th...
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones
Apr 24, 2026
On April 24, 2026, NeuroSense Therapeutics announced that Chief Medical Officer Dr. Ferenc Tracik will step down from his role, effective April 27, 2026, and transition to serving the company as an independent advisor. The company emphasized that ...
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC
Apr 6, 2026
On April 6, 2026, NeuroSense Therapeutics announced that Brazil’s patent office granted a patent covering the composition of its lead drug candidate PrimeC, following earlier patent approvals in the U.S. and Australia. The Brazilian patent s...
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status
Apr 3, 2026
On April 3, 2026, NeuroSense Therapeutics disclosed that it received two Nasdaq notices on April 2 stating its shares failed to meet minimum bid price and market value of listed securities requirements between February 18 and March 31, 2026. The c...
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial
Mar 31, 2026
On March 31, 2026, NeuroSense Therapeutics reported its financial results for the year ended December 31, 2025 and detailed a pivotal year in which PrimeC progressed from a successful Phase 2b ALS program into a late-stage clinical asset with FDA ...
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens
Mar 24, 2026
On March 24, 2026, NeuroSense Therapeutics reported that it has rescheduled a pre-New Drug Submission meeting with Health Canada to May 2026 to incorporate new clinical, biomarker and survival data for its ALS and Alzheimer’s candidate Prime...
NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology
Mar 16, 2026
On March 16, 2026, NeuroSense Therapeutics reported that results from its PARADIGM Phase 2b clinical trial of PrimeC in people living with ALS were published in JAMA Neurology, underscoring the therapy’s strong safety profile over 18 months ...
NeuroSense Shareholders Approve Increase in Registered Share Capital
Mar 11, 2026
On March 10, 2026, NeuroSense Therapeutics Ltd. held a special meeting of shareholders at which investors approved an amendment to the company’s articles of association to increase its registered share capital. This change, formalized in a r...
NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial
Feb 18, 2026
On February 18, 2026, NeuroSense Therapeutics reported new long-term survival data from its completed PARADIGM Phase 2b trial of PrimeC in ALS, showing a clinically meaningful and statistically significant survival advantage for patients continuou...
NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase
Feb 13, 2026
NeuroSense Therapeutics Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on February 13, 2026, announcing a special meeting of shareholders to be held on March 10, 2026, at the company’s offices in Herzliya, Israel. Sha...
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042
Feb 9, 2026
On February 9, 2026, NeuroSense Therapeutics said the Australian Patent Office granted a new patent covering the composition of its lead ALS and Alzheimer’s candidate, PrimeC, extending exclusivity for the therapy in that market through Octo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.